Barclays upgraded CVS Health Inc (NYSE:CVS) on higher Pharmacy & Consumer Wellness (PCW) estimates as headwinds are offset by ...

First Solar ( FSLR) was the worst-performing stock in the S&P 500 when Jefferies lowered its price target, warning that ...

Analysts upgraded shares of the healthcare company to Overweight from Equal Weight and raised their price target to $82.

Fintel reports that on October 10, 2024, Barclays upgraded their outlook for CVS Health (NYSE:CVS) from Equal-Weight to ...

CVS Health (CVS) stock gained as Barclays upgraded the company, citing a compelling path to margin recovery in its Medicare ...

CVS Health (CVS – Research Report) received a Buy rating and an $82.00 price target from Barclays analyst Andrew Mok CFA today. The ...

On Oct. 8, Keybanc analyst John Vinh maintained Micron Technology with an Overweight and lowered the price target from $145 ...

Barclays analyst Andrew Mok CFA maintained a Hold rating on CVS Health (CVS – Research Report) today and set a price target of $63.00.

The drugstore chain's board has hired bankers to help review options for the company, including a potential breakup. Shares ...

Sixty-two percent of people currently enrolled in Medicare Advantage plans that cover prescription drugs are covered by plans ...

CVS Health (CVS) business segment earns attention as multiple reports indicated on Monday that the healthcare conglomerate is ...

CVS, Considering a Breakup, Will Find It's Hard to Do Splitting the healthcare company into stand-alone pharmacy or health insurance ... Worry About iPhone Demand. Barclays analyst Tim Long ...